Literature DB >> 23808472

Current landscape and new paradigms of proficiency testing and external quality assessment for molecular genetics.

Lisa V Kalman1, Ira M Lubin, Shannon Barker, Desiree du Sart, Rob Elles, Wayne W Grody, Mario Pazzagli, Sue Richards, Iris Schrijver, Barbara Zehnbauer.   

Abstract

CONTEXT: Participation in proficiency testing (PT) or external quality assessment (EQA) programs allows the assessment and comparison of test performance among different clinical laboratories and technologies. In addition to the approximately 2300 tests for individual genetic disorders, recent advances in technology have enabled the development of clinical tests that quickly and economically analyze the entire human genome. New PT/EQA approaches are needed to ensure the continued quality of these complex tests.
OBJECTIVES: To review the availability and scope of PT/EQA for molecular genetic testing for inherited conditions in Europe, Australasia, and the United States; to evaluate the successes and demonstrated value of available PT/EQA programs; and to examine the challenges to the provision of comprehensive PT/EQA posed by new laboratory practices and methodologies. DATA SOURCES: The available literature on this topic was reviewed and supplemented with personal experiences of several PT/EQA providers.
CONCLUSIONS: Proficiency testing/EQA schemes are available for common genetic disorders tested in many clinical laboratories but are not available for most genetic tests offered by only one or a few laboratories. Provision of broad, method-based PT schemes, such as DNA sequencing, would allow assessment of many tests for which formal PT is not currently available. Participation in PT/EQA improves the quality of testing by identifying inaccuracies that laboratories can trace to errors in their testing processes. Areas of research and development to ensure that PT/EQA programs can meet the needs of new and evolving genetic tests and technologies are identified and discussed.

Entities:  

Mesh:

Year:  2013        PMID: 23808472      PMCID: PMC4684176          DOI: 10.5858/arpa.2012-0311-RA

Source DB:  PubMed          Journal:  Arch Pathol Lab Med        ISSN: 0003-9985            Impact factor:   5.534


  46 in total

1.  HLA-A*2626, a new allele identified through external proficiency-testing exercise.

Authors:  E Longhi; S Frison; I Colombini; A Malagoli; L Crespiatico; F Poli
Journal:  Tissue Antigens       Date:  2005-10

2.  Methodologic European external quality assurance for DNA sequencing: the EQUALseq program.

Authors:  Parviz Ahmad-Nejad; Alexandra Dorn-Beineke; Ulrike Pfeiffer; Joachim Brade; Wolf-Jochen Geilenkeuser; Simon Ramsden; Mario Pazzagli; Michael Neumaier
Journal:  Clin Chem       Date:  2006-01-26       Impact factor: 8.327

3.  EQUAL-qual: a European program for external quality assessment of genomic DNA extraction and PCR amplification.

Authors:  Claudio Orlando; Paolo Verderio; Ronald Maatman; Jan Danneberg; Simon Ramsden; Michael Neumaier; Domenica Taruscio; Vincenzo Falbo; Robert Jansen; Claudia Casini-Raggi; Francesca Malentacchi; Ettore Marubini; Sara Pizzamiglio; Kris Vernelen; Jean-Claude Libeer; Vladimir Palicka; Mario Pazzagli
Journal:  Clin Chem       Date:  2007-07       Impact factor: 8.327

4.  Monitoring standards for molecular genetic testing in the United Kingdom, the Netherlands, and Ireland.

Authors:  Simon C Ramsden; Zandra Deans; David O Robinson; Roger Mountford; Erik A Sistermans; Wayne W Grody; Shirley McQuaid; Simon J Patton; Susan A R Stenhouse
Journal:  Genet Test       Date:  2006

5.  An Italian program of external quality control for quantitative assays based on real-time PCR with Taq-Man probes.

Authors:  Claudia Casini Raggi; Paolo Verderio; Mario Pazzagli; Ettore Marubini; Lisa Simi; Pamela Pinzani; Angelo Paradiso; Claudio Orlando
Journal:  Clin Chem Lab Med       Date:  2005       Impact factor: 3.694

6.  American College of Medical Genetics recommendations for the design and performance expectations for clinical genomic copy number microarrays intended for use in the postnatal setting for detection of constitutional abnormalities.

Authors:  Hutton M Kearney; Sarah T South; Daynna J Wolff; Allen Lamb; Ada Hamosh; Kathleen W Rao
Journal:  Genet Med       Date:  2011-07       Impact factor: 8.822

7.  College of American Pathologists/American College of Medical Genetics proficiency testing for constitutional cytogenomic microarray analysis.

Authors:  Arthur R Brothman; Michelle M Dolan; Barbara K Goodman; Jonathan P Park; Diane L Persons; Debra F Saxe; James H Tepperberg; Karen D Tsuchiya; Daniel L Van Dyke; Kathleen S Wilson; Daynna J Wolff; Karl S Theil
Journal:  Genet Med       Date:  2011-09       Impact factor: 8.822

8.  External quality assessment for mutation detection in the BRCA1 and BRCA2 genes: EMQN's experience of 3 years.

Authors:  C R Mueller; U Kristoffersson; D Stoppa-Lyonnet
Journal:  Ann Oncol       Date:  2004       Impact factor: 32.976

9.  Experience and outcome of 3 years of a European EQA scheme for genetic testing of the spinocerebellar ataxias.

Authors:  Sara Seneca; Michael A Morris; Simon Patton; Rob Elles; Jorge Sequeiros
Journal:  Eur J Hum Genet       Date:  2008-02-27       Impact factor: 4.246

10.  Good laboratory practices for molecular genetic testing for heritable diseases and conditions.

Authors:  Bin Chen; MariBeth Gagnon; Shahram Shahangian; Nancy L Anderson; Devery A Howerton; Joe D Boone
Journal:  MMWR Recomm Rep       Date:  2009-06-12
View more
  12 in total

Review 1.  Molecular Biomarkers for the Evaluation of Colorectal Cancer: Guideline From the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and American Society of Clinical Oncology.

Authors:  Antonia R Sepulveda; Stanley R Hamilton; Carmen J Allegra; Wayne Grody; Allison M Cushman-Vokoun; William K Funkhouser; Scott E Kopetz; Christopher Lieu; Noralane M Lindor; Bruce D Minsky; Federico A Monzon; Daniel J Sargent; Veena M Singh; Joseph Willis; Jennifer Clark; Carol Colasacco; R Bryan Rumble; Robyn Temple-Smolkin; Christina B Ventura; Jan A Nowak
Journal:  J Mol Diagn       Date:  2017-02-06       Impact factor: 5.568

Review 2.  Guidelines for Validation of Next-Generation Sequencing-Based Oncology Panels: A Joint Consensus Recommendation of the Association for Molecular Pathology and College of American Pathologists.

Authors:  Lawrence J Jennings; Maria E Arcila; Christopher Corless; Suzanne Kamel-Reid; Ira M Lubin; John Pfeifer; Robyn L Temple-Smolkin; Karl V Voelkerding; Marina N Nikiforova
Journal:  J Mol Diagn       Date:  2017-03-21       Impact factor: 5.568

Review 3.  Assuring the Quality of Next-Generation Sequencing in Clinical Microbiology and Public Health Laboratories.

Authors:  Amy S Gargis; Lisa Kalman; Ira M Lubin
Journal:  J Clin Microbiol       Date:  2016-08-10       Impact factor: 5.948

4.  Molecular Biomarkers for the Evaluation of Colorectal Cancer.

Authors:  Antonia R Sepulveda; Stanley R Hamilton; Carmen J Allegra; Wayne Grody; Allison M Cushman-Vokoun; William K Funkhouser; Scott E Kopetz; Christopher Lieu; Noralane M Lindor; Bruce D Minsky; Federico A Monzon; Daniel J Sargent; Veena M Singh; Joseph Willis; Jennifer Clark; Carol Colasacco; R Bryan Rumble; Robyn Temple-Smolkin; Christina B Ventura; Jan A Nowak
Journal:  Am J Clin Pathol       Date:  2017-02-03       Impact factor: 2.493

5.  The homogeneous mutation status of a 22 gene panel justifies the use of serial sections of colorectal cancer tissue for external quality assessment.

Authors:  Jeroen R Dijkstra; Bastiaan B J Tops; Iris D Nagtegaal; J Han J M van Krieken; Marjolijn J L Ligtenberg
Journal:  Virchows Arch       Date:  2015-06-06       Impact factor: 4.064

6.  Variation in pre-PCR processing of FFPE samples leads to discrepancies in BRAF and EGFR mutation detection: a diagnostic RING trial.

Authors:  Joshua R Kapp; Tim Diss; James Spicer; Michael Gandy; Iris Schrijver; Lawrence J Jennings; Marilyn M Li; Gregory J Tsongalis; David Gonzalez de Castro; Julia A Bridge; Andrew Wallace; Joshua L Deignan; Sandra Hing; Rachel Butler; Eldo Verghese; Gary J Latham; Rifat A Hamoudi
Journal:  J Clin Pathol       Date:  2014-11-27       Impact factor: 3.411

7.  Reliability and performance of commercial RNA and DNA extraction kits for FFPE tissue cores.

Authors:  Palak G Patel; Shamini Selvarajah; Karl-Philippe Guérard; John M S Bartlett; Jacques Lapointe; David M Berman; John B A Okello; Paul C Park
Journal:  PLoS One       Date:  2017-06-22       Impact factor: 3.240

8.  External Quality Assessment for Next-Generation Sequencing-Based HIV Drug Resistance Testing: Unique Requirements and Challenges.

Authors:  Emma R Lee; Feng Gao; Paul Sandstrom; Hezhao Ji
Journal:  Viruses       Date:  2020-05-16       Impact factor: 5.048

Review 9.  Development and Characterization of Reference Materials for Genetic Testing: Focus on Public Partnerships.

Authors:  Lisa V Kalman; Vivekananda Datta; Mickey Williams; Justin M Zook; Marc L Salit; Jin Yeong Han
Journal:  Ann Lab Med       Date:  2016-11       Impact factor: 3.464

10.  The reliable assurance of detecting somatic mutations in cancer-related genes by next-generation sequencing: the results of external quality assessment in China.

Authors:  Rui Zhang; Jiansheng Ding; Yanxi Han; Lang Yi; Jiehong Xie; Xin Yang; Gaowei Fan; Guojing Wang; Mingju Hao; Dong Zhang; Kuo Zhang; Guigao Lin; Jinming Li
Journal:  Oncotarget       Date:  2016-09-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.